Massimo Giusti1, Miranda Mittica2, Paola Comite3, Claudia Campana2, Stefano Gay2, Michele Mussap3. 1. Endocrine Unit, University Hospital San Martino, Genoa, Italy. magius@unige.it. 2. Endocrine Unit, University Hospital San Martino, Genoa, Italy. 3. Endocrine Unit and Laboratory Medicine Unit, University Hospital San Martino, Genoa, Italy.
Abstract
PURPOSE: In recent years, anti-Mullerian hormone (AMH) has been considered a reliable index of ovarian reserve. There are few data on AMH values in thyroid cancer. The aim of this study was to evaluate AMH levels in pre-menopausal women with a history of low-risk thyroid cancer. METHODS: Thirty-four women (aged 40.7 ± 6.7 years) were studied 7.1 ± 0.9 years after surgery and at least one RAI treatment. A group of 23 thyroid cancer women (41.6 ± 7.4 years) who had undergone only thyroidectomy served as controls. AMH, follicle-stimulating hormone (FSH) and estradiol were assayed on days 2-3, and prolactin and progesterone levels on days 21-24 of the menstrual cycle. RESULTS: Pregnancy (RAI group 62%; control group 61%) and miscarriage rates (18% and 26%) were similar. AMH levels were similar in the RAI (10.7 ± 1.7 pmol/l) and control (17.5 ± 4.7 pmol/l) groups. Regular menses were reported in 41% and 52% of RAI and control subjects, respectively. Non-ovulatory cycles were noted in 26% and 35% of RAI and control women, respectively. AMH levels were found to be negatively correlated with age (RAI group P = 0.0003; control group P = 0.0001) and FSH, and positively correlated with progesterone, but not with the other hormonal parameters. CONCLUSIONS: AMH should replace FSH in the evaluation of gonadal reserve in pre-menopausal thyroid cancer women. At present, age is the only predictor of AMH levels. About one out of two women with a history of thyroid cancer suffers from menstrual dysregulation, but infertility must be considered a low risk.
PURPOSE: In recent years, anti-Mullerian hormone (AMH) has been considered a reliable index of ovarian reserve. There are few data on AMH values in thyroid cancer. The aim of this study was to evaluate AMH levels in pre-menopausal women with a history of low-risk thyroid cancer. METHODS: Thirty-four women (aged 40.7 ± 6.7 years) were studied 7.1 ± 0.9 years after surgery and at least one RAI treatment. A group of 23 thyroid cancerwomen (41.6 ± 7.4 years) who had undergone only thyroidectomy served as controls. AMH, follicle-stimulating hormone (FSH) and estradiol were assayed on days 2-3, and prolactin and progesterone levels on days 21-24 of the menstrual cycle. RESULTS: Pregnancy (RAI group 62%; control group 61%) and miscarriage rates (18% and 26%) were similar. AMH levels were similar in the RAI (10.7 ± 1.7 pmol/l) and control (17.5 ± 4.7 pmol/l) groups. Regular menses were reported in 41% and 52% of RAI and control subjects, respectively. Non-ovulatory cycles were noted in 26% and 35% of RAI and control women, respectively. AMH levels were found to be negatively correlated with age (RAI group P = 0.0003; control group P = 0.0001) and FSH, and positively correlated with progesterone, but not with the other hormonal parameters. CONCLUSIONS:AMH should replace FSH in the evaluation of gonadal reserve in pre-menopausal thyroid cancerwomen. At present, age is the only predictor of AMH levels. About one out of two women with a history of thyroid cancer suffers from menstrual dysregulation, but infertility must be considered a low risk.
Entities:
Keywords:
Anti-mullerian hormone; Radioactive iodine; Thyroid cancer
Authors: D Unuane; B Velkeniers; B Bravenboer; P Drakopoulos; H Tournaye; J Parra; M De Brucker Journal: Hum Reprod Date: 2017-04-01 Impact factor: 6.918
Authors: Anne Z Steiner; Amy H Herring; James S Kesner; Juliana W Meadows; Frank Z Stanczyk; Steven Hoberman; Donna D Baird Journal: Obstet Gynecol Date: 2011-04 Impact factor: 7.661
Authors: Chelsea Anderson; Stephanie M Engel; Mark A Weaver; Jose P Zevallos; Hazel B Nichols Journal: Int J Cancer Date: 2017-08-16 Impact factor: 7.396
Authors: Anna M Sawka; Deepak C Lakra; Jane Lea; Bandar Alshehri; Richard W Tsang; James D Brierley; Sharon Straus; Lehana Thabane; Amiram Gafni; Shereen Ezzat; Susan R George; David P Goldstein Journal: Clin Endocrinol (Oxf) Date: 2008-02-13 Impact factor: 3.478
Authors: Richard A Anderson; Ellen Anckaert; Ernesto Bosch; Didier Dewailly; Cheryl E Dunlop; Daniel Fehr; Luciano Nardo; Johan Smitz; Kelton Tremellen; Barbara Denk; Andrea Geistanger; Martin Hund Journal: Fertil Steril Date: 2015-02-11 Impact factor: 7.329